AbbVie

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade AbbVie 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ABBV

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. 

CEO
Robert A. Michael
CEORobert A. Michael
Employees
57,000
Employees57,000
Headquarters
North Chicago, Illinois
HeadquartersNorth Chicago, Illinois
Founded
2011
Founded2011
Employees
57,000
Employees57,000

ABBV Key Statistics

Market cap
510.38B
Market cap510.38B
Price-Earnings ratio
48.80
Price-Earnings ratio48.80
Dividend yield
2.44%
Dividend yield2.44%
Average volume
4.51M
Average volume4.51M
High today
$290.23
High today$290.23
Low today
$284.00
Low today$284.00
Open price
$286.87
Open price$286.87
Volume
1.88M
Volume1.88M
52 Week high
$302.93
52 Week high$302.93
52 Week low
$190.75
52 Week low$190.75

Stock Snapshot

AbbVie(ABBV) stock is priced at $288.74, giving the company a market capitalization of 510.38B. It carries a P/E multiple of 48.80 and pays a dividend yield of 2.44%.

As of 2026-11-20, AbbVie(ABBV) stock has fluctuated between $284.00 and $290.23. The current price stands at $288.74, placing the stock +1.7% above today's low and -0.5% off the high.

The AbbVie(ABBV)'s current trading volume is 1.88M, compared to an average daily volume of 4.51M.

In the last year, AbbVie(ABBV) shares hit a 52-week high of $302.93 and a 52-week low of $190.75.

In the last year, AbbVie(ABBV) shares hit a 52-week high of $302.93 and a 52-week low of $190.75.

ABBV News

TipRanks 23m
AbbVie Advances NOA HYDRATION Skin-Quality Study in China

Abbvie (ABBV) announced an update on their ongoing clinical study. Study Overview: AbbVie is studying NOA HYDRATION to assess whether it can safely improve fac...

The Motley Fool 55m
AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy for 2027?

Free Article Explore Premium Services AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy for 2027? Eli Lilly's revenue is climbing at a pace AbbVie ca...

AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy for 2027?
Simply Wall St 23h
Why Owning AbbVie Through ETFs Could Change The Risks You Carry

Anyone buying AbbVie stock directly takes on its company-specific risks alone. Simply Wall St notes that AbbVie carries a high level of debt and that its divide...

Why Owning AbbVie Through ETFs Could Change The Risks You Carry

Analyst ratings

77%

of 31 ratings
Buy
77.4%
Hold
19.4%
Sell
3.2%

More ABBV News

TipRanks 2d
AbbVie Advances ABBV-2294 Study for Rare Systemic Sclerosis

Abbvie (ABBV) announced an update on their ongoing clinical study. Study Overview: AbbVie’s official study title is “A Phase 2b/3 Multicenter, Randomized, Doub...

Benzinga 2d
Amazon, Marriott, Berkshire Hathaway And A Health Care Stock: CNBC’s ‘Final Trades’

On CNBC’s “Halftime Report Final Trades,” Joshua Brown, co-founder and CEO of Ritholtz Wealth Management, picked Berkshire Hathaway Inc. (NYSE:BRK). On Oct. 22...

Amazon, Marriott, Berkshire Hathaway And A Health Care Stock: CNBC’s ‘Final Trades’
TipRanks 2d
AbbVie price target raised to $349 from $303 at Piper Sandler

Piper Sandler raised the firm’s price target on AbbVie (ABBV) to $349 from $303 and keeps an Overweight rating on the shares. Beyond an attractive top-line/EBIT...

Simply Wall St 3d
AbbVie Taps AI Drug Discovery Partnership To Extend Its Research Pipeline

AbbVie (NYSE:ABBV) has entered a new AI-driven drug discovery partnership with biotech firm Iambic. The collaboration focuses on applying advanced algorithms t...

AbbVie Taps AI Drug Discovery Partnership To Extend Its Research Pipeline
TipRanks 4d
AbbVie put volume heavy and directionally bearish

Bearish flow noted in AbbVie (ABBV) with 7,538 puts trading, or 1.5x expected. Most active are 11/27 weekly 287.5 puts and Jun-27 195 puts, with total volume in...

Simply Wall St 4d
Is AbbVie Undervalued On Its Humira Transition And Board Change?

Board change and new partnerships put AbbVie in focus AbbVie (ABBV) moved into the spotlight after director Jennifer L. Davis resigned from its board following...

Is AbbVie Undervalued On Its Humira Transition And Board Change?
TipRanks 4d
AbbVie price target raised to $335 from $325 at Barclays

Barclays raised the firm’s price target on AbbVie (ABBV) to $335 from $325 and keeps an Overweight rating on the shares post the Q3 report. In the current envir...

People also own

Based on the portfolios of people who own ABBV. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.